Ergothioneine Skin Hydration Randomized Trial: What the Evidence Says

Quick Answer

Ergothioneine Skin Hydration Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Nevertheless, the procedure carries a potential risk of post-inflammatory hyperpigmentation (PIH), especially among individuals with Fitzpatrick skin type IV, which is prevalent in the Chinese population. [He Yixuan (2026); evidence level 2]
• At the end of the study, the efficacy rates for all symptoms were found to be higher on the test sides than on the control sides (Figure ). [He Yixuan (2026); evidence level 2]
• In addition, global life expectancy has increased from 60 to 70 years for both males and females over the last 20 years (B). [Sun Yidan (2026); evidence level 4]
• Aging is closely associated with a high incidence of multiple chronic diseases, including congestive heart failure, myocardial infarction, dementia, stroke, most cancers, diabetes and metabolic disorders, renal dysfunction, chronic lung disease, osteoporosis, arthritis, and vision loss. [Sun Yidan (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For ergothioneine skin hydration randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• He Yixuan (2026). Efficacy of 1064‐Nm Picosecond Nd: YAG Laser in Treating Facial Photoaging and Improving Skin Barrier Enhanced by a Multi‐Beneficial Composition Formulation: A Blinded Randomized Clinical Trial Study. DOI: 10.1111/jocd.70886. PMCID: PMC13144715. PMID: 42087413. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13144715/
• Sun Yidan (2026). An integrated anti-aging framework targeting NAD + homeostasis, mitochondrial quality control, and redox stability: Roles of NMN/NR, PQQ, and EGT. DOI: 10.1016/j.redox.2026.104191. PMCID: PMC13144588. PMID: 42068909. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13144588/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.